Daclatasvir Dihydrochloride
Inkcazo
I-Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) inamandla kwaye iyasebenza ngomlomo.Iprotheni ye-HCV NS5Ainhibitor ngeEC50s uluhlu lwe-9-146 pM yeezininzi HCV replicon genotypes.I-Daclatasvir dihydrochloride ikwayi-aI-anion ephilayo ehambisa i-polypeptide 1B (OATP1B)kwayeOATP1B3inhibitor ngeIC50s ka-1.5 µM kunye ne-3.27 µM, ngokulandelelanayo.
IC50& Ekujoliswe kuko
EC50: 50 pM (HCV replicon genotype 1a), 9 pM (HCV replicon genotype 1b), 71 pM (HCV replicon genotype 2a), 146 pM (HCV replicon genotype 3a), 12 pM (HCV replicon genotype 34a) HCV replicon genotype 5a)[1]
I-Kd: 8 nM (NS5A33-202) kunye ne-210 nM (NS5A26-202)[2]
I-IC50: 1.5 µM (OATP1B) kunye ne-3.27 µM (OATP1B3)[3]
I-In vitro
I-Daclatasvir (BMS-790052) ibonisa umsebenzi onamandla wokuthintela kuzo zonke ii-genotypes ezivavanyiweyo, kunye ne-EC50amaxabiso ukusuka kwi-9 pM ukuya kwi-146 pM.I-Daclatasvir inqanda i-HCV replicon genotype 1a, 1b, 2a, 3a, 4a kunye ne-5a kunye ne-EC50amaxabiso e-50 pM, 9 pM, 71 pM, 146 pM, 12 pM kunye ne-33 pM, ngokulandelanayo.I-Daclatasvir yi-inhibitor enamandla ye-JFH-1 genotype 2a intsholongwane eyosulelayo ephindaphinda kwinkcubeko yeseli (EC50=28pm)[1].I-Daclatasvir (BMS-790052) ibophelela ngokuqinileyo kwi-NS5A33-202 kunye ne-NS5A26-202 kunye ne-Kds ye-8 nM kunye ne-210 nM, ngokulandelelanayo[2].
Ugcino
| Umgubo | -20°C | Iminyaka emi-3 |
| 4°C | iminyaka eyi-2 | |
| Kwi-solvent | -80°C | Iinyanga ezi-6 |
| -20°C | Inyanga eyi-1 |
Ulingo lwezonyango
| Inombolo ye-NCT | Umxhasi | Imeko | Umhla wokuqala | Isigaba |
| NCT03369327 | IYunivesithi yaseTehran yeNzululwazi yezoNyango|RojanPharma Pharmaceutical Company | Usulelo lweNtsholongwane yeHepatitis C, iMpendulo kuNyango lwe-|Human Immunodeficiency Virus | NgoJanuwari 1, 2017 | Inqanaba lesi-3 |
| NCT03485846 | R-Pharm|Almedis | IHepatitis C eNgapheliyo iGenotype 1b | NgoNovemba 27, 2017 | Inqanaba lesi-2 |
| NCT01016912 | Bristol-Myers Squibb | Usulelo lweHepatitis C | Disemba 2009 | Inqanaba lesi-2 |
| NCT01629732 | Bristol-Myers Squibb | Intsholongwane yeHepatitis C | Matshi 2013 | Inqanaba lesi-2 |
| NCT01497834 | Bristol-Myers Squibb | IHepatitis C | NgoJanuwari 2012 | Inqanaba lesi-3 |
| NCT01973049 | Bristol-Myers Squibb | IHepatitis C | Disemba 2013 | Inqanaba lesi-3 |
| NCT00663208 | Bristol-Myers Squibb | IHepatitis C engapheliyo | Meyi 2008 | Inqanaba lesi-2 |
| NCT02576314 | Iziko loPhando loLuntu kunye neMpilo|Beijing 302 Hospital | Usulelo lwe-Hepatitis C olungapheliyo | Meyi 2015 | Inqanaba lesi-3 |
| NCT02756936 | Iziko loPhando lokwenyani, eYiputa|Zeta Pharma Pharmaceutical Industries | Usempilweni | NgoFebruwari 2016 | Inqanaba loku-1 |
| NCT02771405 | IHepatology yeSizwe kunye neTropical Medicine Research Institute|Dyunivesithi yaseCairo | IHepatitis C, Engapheliyo|Hepatocellular Carcinoma | Matshi 2016 | Inqanaba lesi-3 |
| NCT03706898 | Viriom | HIV-1-ukosuleleka|Hepatic Impairment | Ngomhla woku-1 kweyeDwarha, ngo-2018 | Inqanaba loku-1 |
| NCT02319031 | Bristol-Myers Squibb | IHepatitis C | NgoFebruwari 2015 | Inqanaba lesi-3 |
| NCT02124044 | AmaZiko eSizwe eZiko lezeMpilo lezeMpilo (CC)|Iziko leSizwe loKwalisa kunye neZifo ezosulelayo (NIAID)|Bristol-Myers Squibb | HIV-HCV | NgoFebruwari 2014 | Inqanaba lesi-2 |
| NCT02551861 | Bristol-Myers Squibb | IHepatitis C | Disemba 2015 | Inqanaba lesi-2 |
| NCT00859053 | Bristol-Myers Squibb | Ukunqongophala kweHepatic | Matshi 2009 | Inqanaba loku-1 |
| NCT01257204 | Bristol-Myers Squibb | Intsholongwane yeHepatitis C | Disemba 2010 | Inqanaba lesi-2 |
| NCT03063879 | IYunivesithi yaseTehran yeSayensi yezoNyango | iYunivesithi yase-Ahvaz Jundishapur yeSayensi yezoNyango | IYunivesithi yaseShiraz yeSayensi yezoNyango | IHepatitis C, Engapheliyo|Ukusilela okuNgapheliyo kwezintso | Ngomhla woku-1 kuTshazimpuzi, ngo-2017 | Inqanaba lesi-4 |
| NCT01017575 | Bristol-Myers Squibb | Usulelo lweHepatitis C | Disemba 2009 | Inqanaba lesi-2 |
| NCT02865369 | USang Gyune Kim | IHepatitis C engapheliyo | NgoSeptemba 2016 |
|
| NCT04070235 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | IHepatitis C, Ezingapheliyo | NgoMatshi 29, 2019 | Isigaba 2|Isigaba 3 |
| NCT03487848 | Bristol-Myers Squibb | IHepatitis C|Isifo Sesibindi Esingapheliyo | Ngomhla we-18 kuCanzibe, ngo-2018 | Inqanaba lesi-2 |
| NCT00904059 | Bristol-Myers Squibb | IHepatitis C | Meyi 2009 | Inqanaba loku-1 |
| NCT02107365 | Iziko leSizwe laseFransi lezeMpilo kunye noPhando lwezoNyango-i-Arhente yeSizwe yaseFransi yoPhando nge-AIDS kunye ne-Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Usulelo | NgoNovemba 2013 | Inqanaba lesi-2 |
| NCT02397395 | Janssen R&D Ireland | Ukukhubazeka kwezintso|Isigaba sokuphela kwesifo sezintso | Meyi 2015 | Inqanaba lesi-2 |
| NCT03169348 | IYunivesithi yaseAssiut | IHepatitis C | NgoNovemba 1, 2017 | Ayingeni |
| NCT02323594 | Bristol-Myers Squibb | Usulelo lweHepatitis C | Disemba 2014 | Inqanaba loku-1 |
| NCT03537196 | IZiko leSizwe lesiFrentshi lezeMpilo kunye noPhando lwezoNyango-i-Arhente yeSizwe yaseFransi yoPhando nge-AIDS kunye ne-Hepatitis ye-Viral (Inserm-ANRS) | IHepatitis C|Ukusetyenziswa Kweziyobisi|Intsholongwane yeHepatitis C | NgoNovemba 13, 2018 | Inqanaba lesi-4 |
| NCT02103569 | Bristol-Myers Squibb | IHepatitis C | Epreli 2014 | Inqanaba loku-1 |
| NCT02772744 | IYunivesithi yaseZagazig | IYunivesithi yaseCairo | IHepatitis C | NgoNovemba 1, 2017 |
|
| NCT01718158 | Bristol-Myers Squibb | IHepatitis C | NgoJanuwari 2013 | Inqanaba lesi-3 |
| NCT02496078 | Bristol-Myers Squibb | IHepatitis C | EyeThupha 2015 | Inqanaba lesi-3 |
| NCT01425970 | Bristol-Myers Squibb | IHepatitis C | Meyi 2012 | Inqanaba lesi-2 |
| NCT01471574 | Bristol-Myers Squibb | IHepatitis C, iGenotype 1 | Disemba 2011 | Inqanaba lesi-3 |
| NCT01573351 | Bristol-Myers Squibb | Intsholongwane yeHepatitis C | Meyi 2012 | Inqanaba lesi-3 |
| NCT01938625 | Janssen R&D Ireland | IHepatitis C, Ezingapheliyo | NgoDisemba 12, 2013 | Inqanaba lesi-2 |
| NCT01492426 | Bristol-Myers Squibb | IHepatitis C | NgoJanuwari 2012 | Inqanaba lesi-3 |
| NCT03480932 | Johns Hopkins Bloomberg School of Public Health|Ziko leSizwe lokuSetyenziswa gwenxa kweZiyobisi (NIDA)|YR Gaitonde Centre for AIDS and Education | IHepatitis C, Ezingapheliyo | NgoFebruwari 2, 2018 | Isigaba 2|Isigaba 3 |
| NCT03163849 | IYunivesithi yaseAssiut | IHepatitis eNgapheliyo c | NgoSeptemba 1, 2019 | Inqanaba lesi-3 |
| NCT01581203 | Bristol-Myers Squibb | Intsholongwane yeHepatitis C | Meyi 2012 | Inqanaba lesi-3 |
| NCT01492504 | Bristol-Myers Squibb | IHepatitis C | NgoFebruwari 7, 2012 |
|
| NCT03686722 | Mohamed Raslan|IYunivesithi yaseAin Shams|Iziko loPhando ngeziyobisi, eCairo, eYiputa | Isifo seswekile, Uhlobo 2|Hepatitis C|Ukusetyenziswana kweziyobisi | NgoSeptemba 9, 2017 | Inqanaba loku-1 |
| NCT02262728 | UPhando noPhuhliso lwaseJanssen, LLC | IHepatitis C, Ezingapheliyo | NgoSeptemba 30, 2014 | Inqanaba lesi-2 |
| NCT02349048 | UPhando noPhuhliso lwaseJanssen, LLC | Intsholongwane yeHepatitis C | NgoJanuwari 2015 | Inqanaba lesi-2 |
| NCT03882307 | IYunivesithi yaseAssiut | IHepatitis C, Ezingapheliyo | Meyi 2020 | Isigaba sokuqala soku-1 |
| NCT02758509 | IParc de Salut Mar | IHepatitis C eNgapheliyo | Isifo sesibindi | NgoJanuwari 1, 2010 |
|
| NCT01795911 | Bristol-Myers Squibb | IHepatitis C | Matshi 2013 | Inqanaba lesi-2 |
| NCT03549832 | IYunivesithi yaseAssiut | IYunivesithi yaseSohag | IYunivesithi yaseSouth Valley | I-HCV Coinfection | NgoJanuwari 1, 2018 | Ayingeni |
| NCT02161939 | Bristol-Myers Squibb | IHepatitis C engapheliyo |
| |
| NCT01309932 | Bristol-Myers Squibb | IHepatitis C | Matshi 2011 | Inqanaba lesi-2 |
| NCT01995266 | Bristol-Myers Squibb | IHepatitis C | NgoFebruwari 28, 2014 | Inqanaba lesi-3 |
| NCT02640157 | AbbVie | Intsholongwane yeHepatitis C eNgapheliyo | | Disemba 2015 | Inqanaba lesi-3 |
| NCT02032875 | Bristol-Myers Squibb | IHepatitis C | Matshi 2014 | Inqanaba lesi-3 |
| NCT02624063 | IYunivesithi yaseFederal yaseSão Paulo | IHepatitis C, Ezingapheliyo | Disemba 2015 | Inqanaba lesi-4 |
| NCT00546715 | Bristol-Myers Squibb | IHepatitis C engapheliyo | Novemba 2007 | Isigaba 1|Isigaba 2 |
| NCT01718145 | Bristol-Myers Squibb | Usulelo lweNtsholongwane yeHepatitis C | NgoNovemba 2012 | Inqanaba lesi-3 |
| NCT01616524 | Bristol-Myers Squibb | Intsholongwane yeHepatitis C (HCV) | NgoJulayi 2012 | Inqanaba lesi-3 |
| NCT02032901 | Bristol-Myers Squibb | IHepatitis C | NgoJanuwari 2014 | Inqanaba lesi-3 |
| NCT03540212 | KwiYunivesithi yaseAin Shams | Usulelo lwe-HCV olungapheliyo | NgoDisemba 10, 2017 | Isigaba 2|Isigaba 3 |
| NCT02097966 | Bristol-Myers Squibb | IHepatitis C engapheliyo |
| |
| NCT02596880 | IYunivesithi yaseTehran yeSayensi yezoNyango | IHepatitis C | Isifo Sesibindi | NgoSeptemba 2015 | Inqanaba lesi-3 |
| NCT04019717 | Inkampani yeAtea Pharmaceuticals, Inc. | IHepatitis C|Hepatitis C, Engapheliyo|Isifo seHepatitis C esiNgapheliyo|Usulelo lweNtsholongwane C | NgoJuni 20, 2019 | Inqanaba lesi-2 |
| NCT02992457 | IYunivesithi yaseTanta | IHepatitis C | NgoJanuwari 2015 | Inqanaba lesi-4 |
| NCT03547895 | IYunivesithi yaseZagazig | I-Cirrhosis ethotyiweyo | NgoJuni 1, 2015 | Ayingeni |
| NCT03004625 | Isibhedlele saseKaohsiung Medical University, iChung-Ho Memorial Hospital|Isibhedlele saseChang Gung Memorial | Isibhedlele seSizwe saseTaiwan, isibhedlele saseTaipei Veterans General, eTaiwan | IHepatitis C | EyeNkanga 2016 | Inqanaba lesi-3 |
| NCT01051414 | Bristol-Myers Squibb | Usulelo lweHepatitis C | Epreli 2010 | Inqanaba lesi-2 |
| NCT02309450 | Iziko leSizwe laseFransi lezeMpilo kunye noPhando lwezoNyango-i-Arhente yeSizwe yaseFransi yoPhando nge-AIDS kunye ne-Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Usulelo | Disemba 2014 | Inqanaba lesi-2 |
| NCT01628692 | Bristol-Myers Squibb|Janssen Research & Development, LLC | Intsholongwane yeHepatitis C | NgoJulayi 2012 | Inqanaba lesi-2 |
| NCT03186313 | Isibhedlele sesibindi sase-Egypt|Isibhedlele saseWadi El Nil | IHepatitis C | NgoSeptemba 2016 | Inqanaba lesi-3 |
| NCT03063723 | Isibhedlele esiNxulumene neSithathu, kwiYunivesithi yaseSun Yat-Sen | IHepatitis C eNgapheliyo (Isifo) | NgoJanuwari 1, 2016 |
|
| NCT00983957 | Bristol-Myers Squibb | IHepatitis C engapheliyo | Okthobha 2009 | Inqanaba loku-1 |
| NCT01725542 | Iziko leSizwe laseFransi lezeMpilo kunye noPhando lwezoNyango-i-Arhente yeSizwe yaseFransi yoPhando nge-AIDS kunye ne-Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | I-HCV-HIV Co-Infection | Disemba 2012 | Inqanaba lesi-2 |
| NCT02282709 | Isiseko soPhando lwesibindi | IHepatitis C engapheliyo | NgoFebruwari 2014 | Inqanaba lesi-3 |
| NCT02032888 | Bristol-Myers Squibb | IHepatitis C | NgoFebruwari 2014 | Inqanaba lesi-3 |
| NCT03247296 | IYunivesithi yaseMTI | IHepatitis C | NgoFebruwari 28, 2017 |
|
| NCT01389323 | Bristol-Myers Squibb | IHepatitis C | NgoSeptemba 2011 | Inqanaba lesi-3 |
| NCT02556086 | Bristol-Myers Squibb | IHepatitis C | Disemba 2015 | Inqanaba lesi-2 |
| NCT01741545 | Bristol-Myers Squibb | Intsholongwane yeHepatitis C | NgoMatshi 31, 2013 | Inqanaba lesi-3 |
| NCT01866930 | Bristol-Myers Squibb | Usulelo lwe-Hepatitis C olungapheliyo | NgoJulayi 11, 2013 | Inqanaba lesi-3 |
| NCT02268864 | Janssen-Cilag International NV | IHepatitis C, Ezingapheliyo | NgoJanuwari 2015 | Inqanaba lesi-2 |
| NCT01797848 | Bristol-Myers Squibb | IHepatitis C | NgoJuni 2014 | Inqanaba lesi-3 |
| NCT03166280 | UEman Sayed Hassan Abd Allah | IYunivesithi yaseAssiut | IHepatitis C | NgoJuni 2017 |
|
| NCT02159352 | Bristol-Myers Squibb | IHepatitis C | NgoJuni 2014 | Inqanaba loku-1 |
| NCT01125189 | Bristol-Myers Squibb | Intsholongwane yeHepatitis C | Julayi 2010 | Inqanaba lesi-2 |
| NCT03748745 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Ukusebenzisana kweziyobisi | NgoNovemba 19, 2018 | Inqanaba loku-1 |
| NCT01012895 | Bristol-Myers Squibb | IHepatitis C engapheliyo | Disemba 2009 | Inqanaba lesi-2 |
| NCT02565888 | IYunivesithi yaseRadboud | IHepatitis C |HIV | EyeNkanga 2015 | Inqanaba loku-1 |
| NCT02555943 | Iziko loPhando loLuntu kunye neMpilo|Beijing 302 Hospital|Nanfang Hospital of Southern Medical University | Usulelo lweHepatitis C oluNgapheliyo|Ukosuleleka kwe-HBV|Ukuvuselelwa kweHepatitis B | NgoFebruwari 2015 | Isigaba 2|Isigaba 3 |
| NCT02304159 | Tarek I. Hassanein, MD, FACP, FAG, AGAF|Southern California Research Centre | IHepatitis C | Isifo Sesibindi | NgoJanuwari 2015 | Inqanaba lesi-4 |
| NCT02580474 | UMyeong Jun Song|Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam National University Hospital|Konyang University Hospital|Isibhedlele seYunivesithi yase-Eulji|Isibhedlele saseSaint Vincent, eKorea|Isibhedlele saseYunivesithi yaseKonkuk|Isibhedlele iCheongju St. Mary's, Cheongju , Korea|Isibhedlele seSeverance|Isibhedlele saseKorea seGuro yeDyunivesithi|Isibhedlele Jikelele sase-Eulji|IYunivesithi yamaKatolika yaseKorea | IHepatitis C | NgoFebruwari 2016 | Inqanaba lesi-4 |
| NCT02104843 | Bristol-Myers Squibb | IHepatitis C | Epreli 2014 | Inqanaba loku-1 |
| NCT01428063 | Bristol-Myers Squibb | Usulelo lweNtsholongwane yeHepatitis C | NgoSeptemba 2011 | Inqanaba lesi-2 |
| NCT02123654 | Bristol-Myers Squibb | Usulelo lweNtsholongwane yeHepatitis C | Epreli 2014 | Inqanaba lesi-3 |
| NCT02565862 | IYunivesithi yaseRadboud | IHepatitis C|Isifo seswekile|Ukuxhathisa kwi-insulin | NgoJanuwari 2016 | Inqanaba loku-1 |
| NCT04211844 | KwiYunivesithi yaseAin Shams | IHepatitis C engapheliyo | Nge-1 kaOkthobha, 2019 |
|
| NCT00874770 | Bristol-Myers Squibb | Usulelo lweHepatitis C | NgoJuni 2009 | Inqanaba lesi-2 |
| NCT03883698 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Ukungaphumeleli kwezintso, okuNgapheliyo|iHepatitis C | NgoMatshi 15, 2019 | Inqanaba lesi-3 |
| NCT01448044 | Bristol-Myers Squibb | IHepatitis C | Disemba 2011 | Inqanaba lesi-3 |
| NCT01359644 | Bristol-Myers Squibb|Pharmacyset | IHepatitis C engapheliyo | NgoJuni 2011 | Inqanaba lesi-2 |
| NCT01842451 | Vertex Pharmaceuticals Incorporated | IHepatitis C|CHC|HCV|Hepatitis C | NgoJuni 2013 | Inqanaba lesi-2 |
| NCT02762448 | Isibhedlele sikaMasipala waseTainan | IHepatitis c | NgoJulayi 2016 |
|
| NCT02473211 | Iziko loPhando loLuntu kunye neMpilo|Beijing 302 Hospital | Usulelo lwe-Hepatitis C olungapheliyo | NgoJanuwari 2015 | Isigaba 2|Isigaba 3 |
| NCT01455090 | Bristol-Myers Squibb | IHepatitis C engapheliyo | NgoNovemba 30, 2011 | Inqanaba lesi-2 |
| NCT03490097 | KwiYunivesithi yaseAin Shams | IHepatitis eNgapheliyo c|Metabolic Syndrome | NgoDisemba 1, 2017 | Isigaba 2|Isigaba 3 |
| NCT01170962 | Bristol-Myers Squibb | Intsholongwane yeHepatitis C | Agasti 2010 | Inqanaba lesi-2 |
| NCT02333292 | Isibhedlele saseValme University|Isibhedlele del SAS de Jerez|Isibhedlele sikaGeneral Universitario Elche|Isibhedlele iLa Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Isibhedlele saseFigueres|Isibhedlele sasePuerto Real|Isibhedlele seYuniversitario Virgen de Laversitaria Isibhedlele Jikelele seUniversitario de Alicante|Isibhedlele seYuniversitario Araba|Isibhedlele iRoyo Vilanova|Isibhedlele saseBurgos|Complejo Hospitalario Universitario de Huelva|Isibhedlele seYunivesiti uReina Sofia de Cordoba|Isibhedlele iYuniversitario Virgen Macarena | Navarra|Hospital Clinico Universitario San Cecilio|Isibhedlele Universitario La Fe|Isibhedlele Jikelele Universitario de Valencia|Isibhedlele Universitario Infanta Leonor|Isibhedlele Universitario de Gran Canaria|Isibhedlele Jikelele seYunivesiti yaseSanta Lucía|Centro Penitenciario yeNgingqi ye-Alicario la Luz|Isibhedlele Jikelele Universitario de Castellón|Isibhedlele iParc Taulí, Sabadell | Usulelo lwe-Hepatitis C olungapheliyo | Disemba 2014 |
|
| NCT03200184 | IYunivesithi yaseTehran yeSayensi yezoNyango | IHepatitis C | NgoSeptemba 1, 2016 | Inqanaba lesi-4 |
| NCT03188276 | Isibhedlele esiNxulumene neSithathu, kwiYunivesithi yaseSun Yat-Sen | IHepatitis C engapheliyo | NgoFebruwari 1, 2016 | Isigaba sokuqala soku-1 |
| NCT01830205 | Bristol-Myers Squibb | IHepatitis C | NgoSeptemba 2012 | Inqanaba loku-1 |
Isindululo18Iiprojekthi zoVavanyo loBulunga ezivunyiweyo4, kwaye6iiprojekthi ziphantsi kolwamkelo.
Inkqubo yolawulo lomgangatho wehlabathi ephucukileyo ibeke isiseko esiluqilima sokuthengisa.
Ukongamela umgangatho kutyhutyha umjikelo wobomi bemveliso ukuqinisekisa umgangatho kunye nesiphumo sonyango.
Iqela leMicimbi yoLawulo lobuGcisa lixhasa iimfuno zomgangatho ngexesha lesicelo nokubhaliswa.
Korea Countec Bottled Packaging Line
Taiwan CVC Bottled UkuPakisha Line
Italy CAM Board Packaging Line
Umatshini wokuQinisa iFette waseJamani
Japan Viswill Tablet Detector
I-DCS Control Room
